Pure Global AI
NCT03018028Completed

Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes

Novo Nordisk A/SPhase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Diabetes,Diabetes Mellitus, Type 2
Drug/Device/Intervention
Semaglutide
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Novo Nordisk A/S
Location
Akita-shi, Akita,Arakawa-ku, Tokyo,Ebina-shi, Kanagawa,Gunma,Kanagawa,Minato-ku, Tokyo,Naka-shi,Osaka-shi, Osaka,Ota-ku, Tokyo,Saga-shi, Saga,Sendai-shi, Miyagi,Suita-shi, Osaka,Tokyo,Tokyo,Tokyo,Toky, Japan
Timeline & enrollment
Phase
Phase 3
Start date
Jan 10, 2017
End date
Aug 15, 2018
Enrollment
243 participants
Primary outcome

Change in HbA1c (Week 26)

Summary

This trial is conducted in Asia. The aim of this trial is to investigate the dose-response
 relationship of once-daily dosing of three dose levels (3, 7 and 14 mg) of oral semaglutide
 versus placebo as monotherapy on glycaemic control in Japanese subjects with type 2 diabetes
 mellitus

ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03018028
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT03018028 through Pure Global AI's free database. This Phase 3 trial is sponsored by Novo Nordisk A/S and is currently Completed. The study focuses on Diabetes,Diabetes Mellitus, Type 2. Target enrollment is 243 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.